Value-Based Pricing

Value-based pricing (VBP) is an efficient method for pricing new drugs. Rate of return pricing could, however, be useful in two cases: treatments for ultra-rare diseases, and ‘cures’ for conditions currently being treated at great expense. Rate of return pricing gives rise to challenges. Two are (i) finding proxy estimates of development costs including failures, and (ii) driving future research towards discovering high-value treatments.

In this OHE Seminar Briefing, Dr Steven Pearson, President of ICER, sets out ICER’s early experiences of using HTA to assess gene therapy in the US, setting out four primary challenges.

Multi-Indication Pricing: Practical Solutions and Steps to Move Forward. A summary of an HTAi panel session.

OHE Lunchtime Seminar with Mariana Mazzucato on Re-imagining Health Innovation to Deliver Public Value. 28 September 2018 12:00-2:00pm.

What would be the price for an orphan drug that generate rates of return no greater/smaller than the industry average? Is it reasonable?

The OHE has published a report exploring the impact on payers, patients and innovators of differential prices for different uses of pharmaceuticals.

OHE, in collaboration with RAND Europe and King’s College, has been awarded a research grant from Cancer Research UK exploring outcome-based payments.

OHE’s Koonal Shah gave a presentation on the evidence of societal support for an end of life premium at the Pharmaccess Leaders Forum in Milan on 5th May.

A special issue of the Journal of Cancer Policy entitled ‘Value and Cancer’ includes three papers authored by OHE researchers.

Rachel Baker of Glasgow Caledonian University and Koonal Shah of OHE discussed societal viewpoints regarding end of life treatments at a recent seminar.